{"filing":{"accession_number":"0001140361-26-037298","cik":"0001472091","ticker":"PDSB","company_name":"PDS Biotechnology Corp","form":"8-K","filing_date":"2026-09-22","report_date":"2026-09-22","primary_document":"ef20082545_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126037298/ef20082545_8k.htm"},"events":[{"id":34194,"run_id":31462,"accession_number":"0001140361-26-037298","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"PDS Biotechnology announced the publication of Phase 2 clinical trial results for PDS0101 in JAMA Oncology, demonstrating a 39.3-month median overall survival in HPV16-positive head and neck cancer patients—substantially exceeding the 17.9-month standard of care benchmark. This represents a material operational/clinical milestone for a late-stage biotech company, affecting investor assessment of the product candidate's development trajectory and commercial potential, though it does not fit the specific categories of earnings release, M\u0026A activity, or other named event types.","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-09-22","form":"8-K","submitted_at":null,"items":[{"id":37863,"accession_number":"0001140361-26-037298","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"PDS Biotechnology announced the publication of Phase 2 clinical trial results for PDS0101 in JAMA Oncology, demonstrating a 39.3-month median overall survival in HPV16-positive head and neck cancer patients—substantially exceeding the 17.9-month standard of care benchmark. This represents a material operational/clinical milestone for a late-stage biotech company, affecting investor assessment of the product candidate's development trajectory and commercial potential, though it does not fit the specific categories of earnings release, M\u0026A activity, or other named event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T12:06:40.417583+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37863,"accession_number":"0001140361-26-037298","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"PDS Biotechnology announced the publication of Phase 2 clinical trial results for PDS0101 in JAMA Oncology, demonstrating a 39.3-month median overall survival in HPV16-positive head and neck cancer patients—substantially exceeding the 17.9-month standard of care benchmark. This represents a material operational/clinical milestone for a late-stage biotech company, affecting investor assessment of the product candidate's development trajectory and commercial potential, though it does not fit the specific categories of earnings release, M\u0026A activity, or other named event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T12:06:40.417583+00:00","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-09-22"}]}